Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40009892
Localisation
Sweden
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
08/02/2024
Statut
Classification
1.5°C
Année cible
2030
Recipharm commits to reduce absolute scope 1 and 2 GHG emissions 42.1% by 2030 from a 2021 base year*. Recipharm also commits to increase active annual sourcing of renewable electricity from 93.5% in 2021 to 100.0% by 2030. Recipharm also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, use of sold products, and end of life treatment of sold products 25.0% within the same timeframe. *The target boundary includes land-related emissions and removals from bioenergy feedstocks.
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
Source : Science Based Targets initiative | Données publiques